華仁藥業, Huaren Pharmaceutical
華仁藥業股份有限公司(簡稱華仁藥業)成立于1998年5月,2001年8月完成股份制改造,是專業生產非PVC軟袋輸液的高新技術企業。公司是由華仁世紀集團控股,紅塔創新投資控股有限公司、廣發信德投資股份有限公司、中國藥科大學等國內知名企業、院校參股的集產、學、研一體的新型股份公司。公司注冊資本2.183635億元,總資產12.4748億元,公司擁有普通型輸液、治療型輸液、營養型輸液三大類產品,共有二十七個品種、六十七個規格的產品成功上市。2010年8月25日,公司在深圳證券交易所創業板正式掛牌上市,首次公開發行股票5360萬股,股票簡稱“華仁藥業”,股票代碼為“300110”。
公司位于青島市高科技工業園西北側,毗鄰海爾工業園、惠特工業園和嶗山風景度假區,風景秀麗,空氣清新,水源來自嶗山地下水,水質優良,符合制藥廠的環境及水源要求。公司占地面積5.9萬平方米,一期工程建筑面積1.36萬平方米,二期工程建筑面積2.08萬平方米。廠區布局合理,綠化優良。
公司一期工程是由國際著名醫藥工程建設公司意大利STERIL公司設計、安裝、調試并實施“交鑰匙工程”。1998年公司從歐洲引進了世界最先進的制水、配液、制袋灌封、滅菌等核心生產設備,保證了產品品質的領先優勢;雙室袋生產線的引進,更是填補了國內空白。
隨著市場的不斷增長,華仁藥業二期工程于2008年4月5日開工,并于2009年8月27日整體通過國家GMP認證;該工程擁有國內同行業最先進的自動化生產線,以及一個全自動的現代化立體倉庫,它的投產成功是華仁藥業發展史上的又一個里程碑;二期工程的建成使我們不但擁有了近億的產能,更增強了我們的產品在質量和成本上的市場競爭力。
醫藥行業是關系國計民生的大行業,是一個決不允許出現劣質不安全產品的行業;正是本著這樣一種對生命健康負責的態度,公司秉持“健康從點滴做起”的企業精神,實施全員、全方位、全過程的質量管理;堅持“健康、環保、安全”的生產理念,嚴格按照國家GMP標準及SFDA要求,對人員、設備、儀器、工藝方法、環境等進行全方位的驗證、管理和控制,并從原料、中間品到成品全過程進行物理、化學、生物學的檢測、管理和控制,達到美國FDA、歐洲藥典標準和國家標準,處于國內領先水平。
在研發方面,公司新擴建的研發中心研發的附加值極高、市場適用性與競爭力較強的腹膜透析液、脂肪乳、氨基酸、代血漿、腸外營養雙室袋等非PVC軟包裝輸液項目也取得了可喜的進展與突破。
公司還堅持管理創新、技術創新、服務創新,積極推進和實施ERP系統的建設,以優化工作流程,提高工作效率。憑借著卓越的產品質量和完善的售后服務,公司產品被客戶廣泛接受和認可,產品成功進入北京、上海、廣東、南京、浙江、湖北、山東、東北三省等全國26個省市;全國已建立了12個銷售中心,在全國非PVC軟袋輸液市場占有率居前三甲。
經過十余年的發展,公司先后取得了“國家重點技術改造‘雙高一優’項目”、“全國AAA級信譽企業”、“山東省質量管理獎”、“山東省著名商標”、“山東省守合同重信用企業”、“2008青島市最具有成長型中小企業”、“青島市改革開放三十年風云企業”、“建國六十周年山東省醫藥行業卓越企業”、“2009年消防安全工作先進單位”、“2009年度紅十字博愛銀獎”、“2009年度中國誠信企業”、“2010年度紅十字博愛銀獎”、“2011年度消防工作先進單位”、第三屆中國優秀醫院服務商品牌“金如意獎”、“中國馳名商標”等一系列榮譽,被福布斯評為“2009福布斯最具潛力中小企業”,并成為中國人民解放軍總后勤部、衛生部應急儲備的定點輸液生產企業。
作為專業生產非PVC軟袋輸液的高新技術企業,華仁藥業以改善人類“后健康”為己任,秉承“輸液質量肩負生命之托,責任重于泰山”的企業理念,用安全、優質的輸液產品和完善的客戶服務回報社會,致力于打造國內一流的非PVC輸液生產基地。
Qingdao Huaren Pharmaceutical Corp.(briefly as Huaren) was founded in May of 1998 and finished its shareholding reform in August of 2001. It is a new high-tech enterprise which is a professional manufacturer of Non-PVC I.V. solution. It is one modern-style joint-stock company covering the production, marketing and R&D of I.V. Solution. The holding company is Qingdao Huaren Group Ltd., enterprises such as HongTa Innovation Investment Co., Ltd., Guangfa Xinde investment Co., LTD and China Pharmaceutical University etc. take the share of Huaren. The company has registered capital of 160 million yuan and permanent assets of 600 million yuan. There are three kinds of injection, conventional injection, therapeutic injection, nutritious injection, with products of 27 kinds and 57 specifications in the market.
The company is located in the northwest of Qingdao High-Tech Industrial Park, adjoins to Haier Industrial Park, Whitt Industrial Garden and Mt. Laoshan scenic spot, with beautiful scenery, fresh air and groundwater resources from Mt. Laoshan which conforms to pharmaceutical manufacturing environment and water resource requirement. The company covers an area of 59,000 square meters, the first stage construction covers an area of 13,600 square meters, and 20,800 square meters for second stage construction. The layout is reasonable and the afforestation is fine.
The first stage construction was totally designed and constructed by STERIL, a famous international medical project-construction corporation in Italy, and carried out the turn-key project. In 1998, Huaren imported its nucleus equipments for water making, solution making, bag making-filling and inspection from Europe; the introduction of double chamber bag production line fills the blank in China.
As the enlargement of market need, Huaren started the second stage construction on April 5th 2008, and passed the State GMP certificate on August 27th 2009. There are the most advanced production lines in the State, and full automated overhead warehouse in the new factory. Its going into production is a milestone in Huaren’s development. After finishing the second stage construction, we have capacity of around 100million bags. It strengthens our competitive strength on production cost and quality in the market.
Pharmaceuticals industry has respect to the national economy and the people's livelihood, should not have any product of inferior quality. Maintaining a high sense of responsibility to lives, the company insists the management philosophy of “Keep Healthy start from dribs and drabs”, and carries out quality control on departmental and overall process, insisting the faith of “Environment-Friendly,Healthy and Safety”. According to Country GMP and SFDA Standards of management, the company carried on omnibearing confirmation, management and control on personnel, equipments, instruments and techniques, environment and so on. Carrying on physical, chemistry and biology examination from raw materials to end production, it reaches the requirements of American FDA, European pharmacopoeia standard and national standards, leading in the state.
On research and development, in the new research and development centre, we have made significant progress and breakthrough in some Non-PVC I.V. solution programs with highly added value and competitive strength in the market, such as fat emulsions, amino acids, and dextran, parenteral nutrition double-chamber bags. Among these programs, the fat emulsions program has finished all study of pharmacy, and has reported to SFDA. Organ preservation and combination connection of Non-PVC I.V. solution bag have already declared the invention patent with proprietary intellectual property rights to the State.